ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Hospital Universitario Virgen de la Victoria
Málaga, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (12)
2021
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
2015
-
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development
Cancer and Metastasis Reviews, Vol. 34, Núm. 4, pp. 823-842
-
Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993
2014
-
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
BMC Cancer, Vol. 14, Núm. 1
-
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014
Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1025-1034
2013
-
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)
Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168
-
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787
2012
-
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 606-612
2011
-
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 179-184
-
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)
Clinical and Translational Oncology, Vol. 13, Núm. 8, pp. 545-551
2010
-
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)
Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803